- Home
- Technology Platforms
- Nonclinical Evaluation
- Safety Evaluation
- Safety Pharmacology Evaluation
All new oligonucleotide therapeutics must undergo nonclinical safety testing prior to the initiation of human clinical trials. A critical component of this process is the conduct of safety pharmacology evaluation, which is a branch of pharmacology specializing in characterizing drug-related changes in the cardiovascular, central nervous, and respiratory systems to ensure that a drug candidate is safe for human use before it progresses to clinical trials.
The safety pharmacology evaluation of oligonucleotide therapeutics requires a scientific and context-specific approach, as each biological model possesses unique pharmacological characteristics that influence the overall nonclinical safety assessment strategy. Alfa Chemistry has a professional technology platform for safety pharmacology evaluation, and our evaluation is based on The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines S6R1 and S7. If you need help, please contact us.
The purpose of nonclinical safety pharmacological evaluation is threefold:
In selecting the species for safety pharmacology evaluation of oligonucleotide therapeutics, the following points be taken into consideration:
With experienced experts and state-of-the-art equipment, Alfa Chemistry is able to provide customers with safety pharmacology evaluation services and related technical advice for oligonucleotide therapeutics. We are committed to:
Our products and services are for research use only and cannot be used for any clinical purposes.